We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Insulin Makers Blame the Payment System for High List Prices
Insulin Makers Blame the Payment System for High List Prices
Congress should eliminate copays for insulin rather than focus on the life-saving biologics’ list price, an executive with one of the nation’s largest drugmakers said Wednesday.